Some aspects of clearance of mitoguazone in cancer patients and experimental cancer models.
Mitoguazone (methylglyoxal-bis(guanyl-hydrazone), MGBG) was studied by its first-pass mechanism in both cancer patients and experimental cancer models. It appears from the study that 90% of MGBG is cleared from the plasma within minutes. 24-h recovery in the urine, however, did not exceed 16% so that 84% of the drug seems to be bound to subcellular compartments. Tissue levels of MGBG in the normal prostate ranged higher than in experimental prostate cancer type 3327 M/G, i.e. enhanced clearance from cancer tissues: polyamine biosynthetic enzymes ornithine decarboxylase as well as S-adenosylmethionine decarboxylase are contrarily affected by MGBG.
D000230:Adenocarcinoma / Q000188:drug therapy*; D012437:Adenosylmethionine Decarboxylase / Q000032:analysis / Q000037:antagonists & inhibitors; D000818:Animals; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D002460:Cell Line; D002478:Cells, Cultured; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D007263:Infusions, Parenteral; D007680:Kidney Neoplasms / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008935:Mitoguazone / Q000008:administration & dosage / Q000378:metabolism* / Q000633:toxicity; D009955:Ornithine Decarboxylase / Q000032:analysis; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D051381:Rats; D011919:Rats, Inbred Strains; D014018:Tissue Distribution
D009955:Ornithine Decarboxylase; D012437:Adenosylmethionine Decarboxylase; D008935:Mitoguazone